Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Good business performance gives Boehringer Ingelheim tailwind for investment in R&D
Search
COVID-19 General Q&A
COVID-19 General Q&A
Submit Your Opportunity
Information on how to submit a partnering opportunity direct to Boehringer Ingelheim’s Business Development & Licensing team
The power of our people
Diversity & Inclusion is an integral part of Boehringer Ingelheim's identity.
Our Partners Bioharmony
Chandra Ghose, Founder and CEO of Bioharmony Therapeutics, talks about the urgent need for developing new antimicrobials and the benefits of partnering with Boehringer Ingelheim.
100-year anniversary of BI in respiratory care
100-year anniversary of Boehringer Ingelheim in respiratory care
equine asthma
Fighting Equine Asthma is a crucial step to improving the well-being of many horses worldwide. The right treatment can make a world of difference.
Human-dog relationship – a historical perspective
The human-dog relationship – a historical perspective
When profitability is just a consequence
Learn how reproductive technologies and animal welfare ensure cows produce more milk, live better and have shorter calving intervals
World Water Day: Good Health Hinges on Good Water
Clean, safe and accessible water is the most basic prerequisite for life and health
Our Partners Harvard
Brock Reeve, Executive Director of the Harvard Stem Cell Institute, talks about the importance of working together to tackle the challenge of fibrosis.
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
2019 performance: stronger foundation to absorb global effects of COVID-19 pandemic
Lameness – a common problem in horses
The causes of lameness, and why there is a clear need for innovation and new treatment options.
Bringing Precision to Psychiatry
Dr. Hugh Marston and Dr. Vikas Mohan Sharma discuss how precision psychiatry can enable people living with mental health conditions to thrive.
Harold Heart and Dorothy Diabetes
People with type 2 diabetes are up to four times more likely to develop cardiovascular disease than people without diabetes.
Oncology
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in oncology.
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
Collaboration Driving Innovation
In conversation with Dr. Megan Grether, Global Head of Business Development & Licensing, Boehringer Ingelheim Animal Health.
Three challenges shape future antiparasitic treatment
The three key challenges that will shape the future of antiparasitic treatment
All hands-on deck to fight the ‘zombie’ rabies virus
We’re teaming up with communities and governments across Southeast Asia to fight rabies through vaccinations, education programs, and partnerships.
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Drugging Cancers Big Four
What does it mean to drug cancer’s “big four”? Learn how Darryl McConnell & his team are tackling one of the biggest scientific conundrums.
Nurjanahs Story
Nurjanah went from a sporty young woman to someone who no longer had the energy to do simple, everyday tasks. She was diagnosed with scleroderma.
Clinical Trial Demonstrates Positive Top-Line Results Reducing Risk Cardiovascular
Clinical Trial Demonstrates Positive Top-Line Results in Reducing the Risk for Cardiovascular Death or Hospitalisation due to Heart Failure
Cardiometabolic Diseases
We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.